Syngene signs 10-year biologics manufacturing agreement with Zoetis

15 July 2022 | News

The agreement is expected to be worth up to $500 million to Syngene over 10 years

Image credit: shutterstock

Image credit: shutterstock

Syngene International has announced the signing of a 10-year agreement with a leading animal health company, Zoetis, to manufacture the drug substance for Librela (bedinvetmab), a first-in-class monoclonal antibody used for treating osteoarthritis in dogs. 


Syngene’s collaboration with Zoetis started in 2011. Over the past 11 years, Syngene has undertaken development work on several monoclonal antibodies for use in animal health, including developing and manufacturing clinical supplies of treatment for allergic or atopic dermatitis, now widely used, and Librela. 


This agreement, initially centred on Librela, paves the way for the development and manufacturing of other molecules in the coming years and is expected to be worth up to $500 million to Syngene over 10 years, subject to regulatory approvals and market demand.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account